Funding information:
Not applicable
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH,
Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel
coronavirus–infected pneumonia. New England Journal of Medicine. 2020
Jan 29.
- Li J, You Z, Wang Q, Zhou Z, Qiu Y, Luo R et al. The epidemic of
2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging
infectious diseases in the future. Microbes and Infection.
2020;22(2):80-85.
- Sharma A, Tiwari S, Deb MK, MARTY JL. Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2): A global pandemic and treatments
strategies. International Journal of Antimicrobial Agents. 2020 Jun
10:106054.
- Coronavirus Update (Live): 13,039,853 Cases and 571,659 Deaths from
COVID-19 Virus Pandemic - Worldometer [Internet].
Worldometers.info. 2020 [cited 13 July 2020]. Available from:
https://www.worldometers.info/coronavirus/
- Romagnoli S, Peris A, De Gaudio AR, Geppetti P. SARS-CoV-2 and
COVID-19: between pathophysiology complexity and therapeutic
uncertainty. Physiological reviews. 2020 Jun 4.
- Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential
therapy for COVID-19. The Lancet Infectious Diseases. 2020 Apr
1;20(4):398-400.
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease
2019 (COVID-19). Drug Discov Ther [Internet]. 2020; 14 (1):
58–60.
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A
systematic review on the efficacy and safety of chloroquine for the
treatment of COVID-19. Journal of critical care. 2020 Mar 10.
- Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D,
Richardson P. COVID-19: combining antiviral and anti-inflammatory
treatments. The Lancet Infectious Diseases. 2020 Apr 1;20(4):400-2.
- Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X,
Zhang X. Effective treatment of severe COVID-19 patients with
tocilizumab. Proceedings of the National Academy of Sciences. 2020 May
19;117(20):10970-5.
- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved
drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral research. 2020 Apr 3:104787.
- Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi
A, Garreta E, Del Pozo CH, Prosper F, Romero JP. Inhibition of
SARS-CoV-2 infections in engineered human tissues using clinical-grade
soluble human ACE2. Cell. 2020 Apr 24.
- Gurwitz D. Angiotensin receptor blockers as tentative SARS‐CoV‐2
therapeutics. Drug development research. 2020 Mar 4.
- Chen YW, Yiu CP, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV)
3C-like protease (3CL pro) structure: virtual screening reveals
velpatasvir, ledipasvir, and other drug repurposing candidates.
F1000Research. 2020;9.
- Wang C, Li W, Drabek D, Okba NM, van Haperen R, Osterhaus AD, van
Kuppeveld FJ, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal
antibody blocking SARS-CoV-2 infection. Nature Communications. 2020
May 4;11(1):1-6.
- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang
M. Hydroxychloroquine, a less toxic derivative of chloroquine, is
effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery.
2020 Mar 18;6(1):1-4.
- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M,
Xing L, Wei J. Treatment of 5 critically ill patients with COVID-19
with convalescent plasma. Jama. 2020 Apr 28;323(16):1582-9.
- Moore N. Chloroquine for COVID-19 Infection. Drug
Saf 43, 393–394 (2020).
https://doi.org/10.1007/s40264-020-00933-4
- Rismanbaf A. Potential treatments for COVID-19; a narrative literature
review. Archives of Academic Emergency Medicine. 2020;8(1).
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
treatments for coronavirus disease 2019 (COVID-19): a review. Jama.
2020 May 12;323(18):1824-36.
- ŞİMŞEK YAVUZ S, ÜNAL S. Antiviral treatment of COVID-19. Turkish
Journal of Medical Sciences. 2020 Apr 2;50.
- Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon
J, Giordanengo V, Vieira VE, Dupont HT, Honoré S. Hydroxychloroquine
and azithromycin as a treatment of COVID-19: results of an open-label
non-randomized clinical trial. International journal of antimicrobial
agents. 2020 Mar 20:105949.
- Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown
apparent efficacy in treatment of COVID-19 associated pneumonia in
clinical studies. Bioscience trends. 2020.
- Casadevall A, Pirofski LA. The convalescent sera option for containing
COVID-19. The Journal of clinical investigation. 2020 Apr
1;130(4):1545-8.
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan
Y. The origin, transmission and clinical therapies on coronavirus
disease 2019 (COVID-19) outbreak–an update on the status. Military
Medical Research. 2020 Dec;7(1):1-0.
- Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li
J, Qian S. Antibody responses to SARS-CoV-2 in patients of novel
coronavirus disease 2019. Clinical Infectious Diseases. 2020 Jan 1.
- Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E,
Song C, Zhan S. In vitro antiviral activity and projection of
optimized dosing design of hydroxychloroquine for the treatment of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical
Infectious Diseases. 2020 Mar 9.
- Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory
responses: from mechanisms to potential therapeutic tools. Virologica
Sinica. 2020 Mar 3:1-6.
- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek
TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS
coronavirus infection and spread. Virology journal. 2005 Dec
1;2(1):69.
- Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S,
Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease
provides a basis for design of improved α-ketoamide inhibitors.
Science. 2020 Apr 24;368(6489):409-12
- Zhang H, Penninger JM, Li Y , Zhong N, Slutsky AS.
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor:
molecular mechanisms and potential therapeutic target. Intensive care
medicine. 2020 Apr;46(4):586-90.
- Nguyen TM, Zhang Y , Pandolfi PP . Virus against virus: a potential
treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses.
- Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y , Timsit JF . Severe
SARS-CoV-2 infections: practical considerations and management
strategy for intensivists. Intensive care medicine. 2020
Apr;46(4):579-82.
- Poe FL, Corn J. N-Acetylcysteine: a potential therapeutic agent for
SARS-CoV-2. Medical Hypotheses. 2020 May 30:109862.
- BIMONTE S, CRISPO A, AMORE A, CELENTANO E, CUOMO A, CASCELLA M.
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical
Findings and Ongoing Clinical Research. In Vivo. 2020 Jun 1;34(3
suppl):1597-602.
- ANDREOU A, TRANTZA S, FILIPPOU D, SIPSAS N, TSIODRAS S. COVID-19: The
Potential Role of Copper and N-acetylcysteine (NAC) in a Combination
of Candidate Antiviral Treatments Against SARS-CoV-2. In Vivo. 2020
Jun 1;34(3 suppl):1567-88.
- Lopes RD, Macedo AV, Moll-Bernardes RJ, Feldman A, Arruda GD, de Souza
AS, de Albuquerque DC, Mazza L, Santos MF , Salvador NZ, Gibson CM.
Continuing versus suspending angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers: Impact on adverse outcomes in
hospitalized patients with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). American Heart Journal. 2020 May 13.
- Ayaz S, Crea F . Targeting SARS-CoV-2 using polycomb inhibitors as
antiviral agents.
- Shu T, Huang M, Di Wu YR, Zhang X, Han Y , Mu J, Wang R, Qiu Y , Zhang
DY , Zhou X. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA
Helicase Activities That Can Be Inhibited by Bismuth Salts. Virologica
Sinica. 2020 Jun 4:1.
- Palanques-Pastor T, López-Briz E, Andrés JL. Involvement of
interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic
option against COVID-19. European Journal of Hospital Pharmacy. 2020
Jun 4.
- Pandey A, Nikam AN, Shreya AB, Mutalik SP , Gopalan D, Kulkarni S,
Padya BS, Fernandes G, Mutalik S, Prassl R. Potential therapeutic
targets for combating SARS-CoV-2: Drug repurposing, clinical trials
and recent advancements. Life Sciences. 2020 Jun 1:117883.
- Ibáñez S, Martínez O, Valenzuela F , Silva F , Valenzuela O.
Hydroxychloroquine and chloroquine in COVID-19: should they be used as
standard therapy?. Clinical Rheumatology. 2020 Jun 3:1.
- Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C, Staudacher DL,
Wengenmayer T. A prospective, randomised, double blind
placebo-controlled trial to evaluate the efficacy and safety of
tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A
structured summary of a study protocol for a randomised controlled
trial. Trials. 2020 Dec;21(1):1-3.
- Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A,
Prajapat M, Shekhar N, Kumar S, Singh R, Singh A. Virological and
clinical cure in COVID‐19 patients treated with hydroxychloroquine: a
systematic review and meta‐analysis. Journal of medical virology. 2020
Apr 16.
- de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y , Thiel V, Narayanan
K, Makino S, Snijder EJ, van Hemert MJ. Cyclosporin A inhibits the
replication of diverse coronaviruses. The Journal of general virology.
2011 Nov;92(Pt 11):2542.
- Abeygunasekera A, Jayasinghe S. Is the anti-filarial drug
diethylcarbamazine useful to treat COVID-19?. Medical Hypotheses. 2020
May 18:109843.
- Biembengut ÍV, de Souza TD. Coagulation modifiers targeting SARS-CoV-2
main protease Mpro for COVID-19 treatment: an in silico approach.
Memórias do Instituto Oswaldo Cruz. 2020;115.
- Irvani SS, Golmohammadi M, Pourhoseingholi MA, Shokouhi S, Darazam IA.
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and
the usual therapeutic regimen to treat adults with moderate to severe
COVID-19: structured summary of a study protocol for a randomized
controlled trial. Trials. 2020 Dec;21(1):1-3.
- Tan EL, Ooi EE, Lin CY , Tan HC, Ling AE, Lim B, Stanton LW.
Inhibition of SARS coronavirus infection in vitro with clinically
approved antiviral drugs. Emerging infectious diseases. 2004 Apr;
10(4):581.
- Chu CM, Cheng VC, Hung IF , Wong MM, Chan KH, Chan KS, Kao RY , Poon
LL, Wong CL, Guan Y , Peiris JS. Role of lopinavir/ritonavir in the
treatment of SARS: initial virological and clinical findings. Thorax.
2004 Mar 1;59(3):252-6.
- Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V,
Giridharan B, Ganesan S, Venugopal A, Venkatesan D, Ganesan H,
Rajagopalan K. COVID-19: A promising cure for the global panic.
Science of The Total Environment. 2020 Apr 4:138277.
- Zhang W, Zhao Y , Zhang F , Wang Q, Li T, Liu Z, Wang J, Qin Y , Zhang
X, Yan X, Zeng X. The use of anti-inflammatory drugs in the treatment
of people with severe coronavirus disease 2019 (COVID-19): The
experience of clinical immunologists from China. Clinical Immunology.
2020 Mar 25:108393.
- Della-Torre E, Della-Torre F , Marija Kusanovic PC, Scotti R,
Alvise-Ramirez G, Dagna L, Tresoldi M. Treating COVID-19 with
colchicine in community healthcare setting. Clinical Immunology
(Orlando, Fla.). 2020 May 31.
- Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J,
Weinberg P , Kirkwood J, Muse A, DeHovitz J, Blog DS. Association of
treatment with hydroxychloroquine or azithromycin with in-hospital
mortality in patients with COVID-19 in New York state. Jama. 2020 May
11.
- Ye M, Fu D, Ren Y , Wang F , Wang D, Zhang F , Xia X, Lv T. Treatment
with convalescent plasma for COVID‐19 patients in Wuhan, China.
Journal of Medical Virology. 2020 Apr 15.
- Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of
corticosteroid treatment on patients with coronavirus infection: a
systematic review and meta-analysis. Journal of Infection. 2020 Apr
10.